Disclosure of interest: FAM, KG, VR, MK, WNW, KB, PH have nothing to disclose Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.03 - EPIDEMIOLOGY & RISK FACTORS P1005 - ESOC25-1187 PREVALENCE AND OUTCOME OF CEREBRAL MICROBLEEDS IN ANTIPHOSPHOLIPID SYNDROME Jonathan Naftali 1 , Rani Barnea 1 , Ruth Eliahou 1 , Tzippy Shochat 1 , Adi Wilf-Yarkoni 1 , Sivan Bloch 2 , Michael Findler 1 , Avi Leader 3 , Walid Saliba 2 , Eitan Auriel 1 1 Rabin medical center, Tel Aviv University, Petah Tikva, Israel, 2 Carmel medical center, Haifa, Israel, 3 Memorial Sloan Kettering Cancer Center, New-York, United States Background and Aims: Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by arterial and venous thrombosis
These certifications require documented procedures, quality control checks, and regulatory oversight
& Salzmann, L
Frequently Asked Questions What is the best copper peptide serum overall
D.DorbalaS.MeserveJ.El FakhriG.SitekA.MooreS
Injectable glutathione can generally be transported during travel with appropriate precautions including maintaining refrigeration using coolers with ice packs during transit, keeping medications in carry-on luggage during air travel to maintain temperature control and prevent loss, carrying a letter from the prescribing provider explaining medical necessity if traveling internationally, and ensuring compliance with destination country regulations regarding injectable medications if traveling abroad
